Tag:
Bayer
Latest Headlines
Latest Headlines
Bayer exec takes reins at J&J's troubled consumer products biz
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and Nesa Nourmohammadi (...
J&J picks Bayer AG exec to solve its consumer product mess
Johnson & Johnson has turned to an outsider to take over its troubled consumer products division and its attendant manufacturing mess.
4SC spotlights partnership talks after liver cancer combo extends survival
The German biotech 4SC AG says its experimental drug resminostat extended overall survival among advanced liver cancer patients by 8 months in Phase II when combined with Bayer's Nexavar.
Pharma pins new social media hopes on Pinterest
Pharma is betting that a picture can be worth a thousand words (or Tweets?) in the world of the social web, with a growing number of major drugmakers raising flags on Pinterest, the social photo-sharing website that attracts millions of monthly visitors, PMLive reports.
Pinterest attracts more pharma outfits
Pinterest trails social media heavyweights such as Facebook and Twitter in popularity among life sciences companies, but the fast-growing photo-sharing social website presents pharma outfits with another platform for reaching millions of people online.
J&J, Bayer try to answer FDA concerns on Xarelto
Bayer and Johnson & Johnson are making another run at getting their anti-clotting drug Xarelto approved for ACS patients, a market that analysts say would take it into blockbuster territory.
J&J, Bayer try to answer FDA concerns on Xarelto
Bayer and Johnson & Johnson are making another run at getting their anti-clotting drug Xarelto approved for ACS patients, a market that analysts say would take it into blockbuster territory.
New Indian price caps would raise another hurdle to Big Pharma
Here's another chapter for the growing treatise known as Emerging Markets Are Tougher Than We Thought, by Big Pharma. India's newly proposed price controls would put another damper on drugmakers, extending caps to branded meds for the first time.
Are emerging markets worth $47B less than pharma expected?
A report from the market research firm GlobalData finds that an unholy convergence of intellectual property worries, price controls and budget cuts is eroding earlier forecasts for emerging-market sales growth.
Xarelto keeps repeat heart attacks at bay, study finds
New data might help Bayer and Johnson & Johnson win a new indication for their Xarelto blood thinner. A new analysis of patients in a late-stage trial found that adding the drug to standard therapy with Plavix and aspirin helped cut the risk of death, heart attack or stroke.
